chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, Injection site pruritus, Injection site urticaria, Nasopharyngitis, Pain
Clinical narrative: General body pain; Cold symptoms; Pelvic pain; Injection site itching; Injection site hives; COVID-19; This spontaneous case was reported by a non-health professional and describes the occurrence of PAIN (General body pain), NASOPHARYNGITIS (Cold symptoms), COVID-19 (COVID-19), PELVIC PAIN (Pelvic pain) and INJECTION SITE PRURITUS (Injection site itching) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No medical history was reported.  Concomitant products included TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In December 2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced PAIN (General body pain), NASOPHARYNGITIS (Cold symptoms), PELVIC PAIN (Pelvic pain), INJECTION SITE PRURITUS (Injection site itching) and INJECTION SITE URTICARIA (Injection site hives). At the time of the report, PAIN (General body pain) and NASOPHARYNGITIS (Cold symptoms) outcome was unknown, COVID-19 (COVID-19) and PELVIC PAIN (Pelvic pain) was resolving and INJECTION SITE PRURITUS (Injection site itching) and INJECTION SITE URTICARIA (Injection site hives) had resolved.            On an unknown date, the patient experienced hives around injection site/ that were itchy, cramps in pelvic pains, moderna vaccine did not agree with body/was sore and achy and cold like symptoms. In December 2021, the patient experienced COVID. On an unknown date, hives around injection site/that were itchy resolved. MODERNA COVID-19 VACCINE (ELASOMERAN) was also considered suspect.   Treatment medication was not reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 59.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Pelvic pain
Clinical narrative: General body pain; Cold symptoms; Pelvic pain; Injection site itching; Injection site hives; COVID-19; This spontaneous case was reported by a non-health professional and describes the occurrence of PAIN (General body pain), NASOPHARYNGITIS (Cold symptoms), COVID-19 (COVID-19), PELVIC PAIN (Pelvic pain) and INJECTION SITE PRURITUS (Injection site itching) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No medical history was reported.  Concomitant products included TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In December 2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced PAIN (General body pain), NASOPHARYNGITIS (Cold symptoms), PELVIC PAIN (Pelvic pain), INJECTION SITE PRURITUS (Injection site itching) and INJECTION SITE URTICARIA (Injection site hives). At the time of the report, PAIN (General body pain) and NASOPHARYNGITIS (Cold symptoms) outcome was unknown, COVID-19 (COVID-19) and PELVIC PAIN (Pelvic pain) was resolving and INJECTION SITE PRURITUS (Injection site itching) and INJECTION SITE URTICARIA (Injection site hives) had resolved.            On an unknown date, the patient experienced hives around injection site/ that were itchy, cramps in pelvic pains, moderna vaccine did not agree with body/was sore and achy and cold like symptoms. In December 2021, the patient experienced COVID. On an unknown date, hives around injection site/that were itchy resolved. MODERNA COVID-19 VACCINE (ELASOMERAN) was also considered suspect.   Treatment medication was not reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19
Symptoms: Immunisation reaction
Clinical narrative: issues with covid vaccine; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (issues with covid vaccine) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis.    The patient had no allergies.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced IMMUNISATION REACTION (issues with covid vaccine). At the time of the report, IMMUNISATION REACTION (issues with covid vaccine) was resolving.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.   The reporter causality for the events of issues with covid vaccine with Humira(adalimumab) was no reasonable possibility.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked in.
Sex: F
Vaccine: COVID19
Symptoms: Cough, Feeling hot
Clinical narrative: Cough; Feeling hot/ FEELING HOT VACUUMING; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough) and FEELING HOT (Feeling hot/ FEELING HOT VACUUMING) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    Concurrent medical conditions included Crohn's disease. Concomitant products included METHOTREXATE for an unknown indication.   On 02-May-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced COUGH (Cough) and FEELING HOT (Feeling hot/ FEELING HOT VACUUMING). At the time of the report, COUGH (Cough) and FEELING HOT (Feeling hot/ FEELING HOT VACUUMING) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation reaction, Pyrexia, Rheumatoid factor, Rheumatoid factor increased
Clinical narrative: Rheumatoid factor increased; COVID VACCINE REACTION; Fever; This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID FACTOR INCREASED (Rheumatoid factor increased), IMMUNISATION REACTION (COVID VACCINE REACTION) and PYREXIA (Fever) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    The patient's past medical history included COVID-19 in 2020.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced IMMUNISATION REACTION (COVID VACCINE REACTION) and PYREXIA (Fever). On an unknown date, the patient experienced RHEUMATOID FACTOR INCREASED (Rheumatoid factor increased). At the time of the report, RHEUMATOID FACTOR INCREASED (Rheumatoid factor increased) and IMMUNISATION REACTION (COVID VACCINE REACTION) had not resolved and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Rheumatoid factor: Elevated.         Concomitant medication was not reported.  In 2020, the patient experienced COVID-19. Patient's Rheumatoid factor was elevated. Patient experienced vaccine reaction and fever. Treatment details were not reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19
Symptoms: Psoriasis, Scar
Clinical narrative: Scar; MAJOR PSORIASIS OUTBREAK; This spontaneous case was reported by a consumer and describes the occurrence of SCAR (Scar) and PSORIASIS (MAJOR PSORIASIS OUTBREAK) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for an unknown indication.    Concomitant products included TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.   In 2013, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 08-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SCAR (Scar) and PSORIASIS (MAJOR PSORIASIS OUTBREAK). At the time of the report, SCAR (Scar) outcome was unknown and PSORIASIS (MAJOR PSORIASIS OUTBREAK) was resolving.            It was unknown if patient was enrolled in COVID-19 vaccine trial. Causality for the Humira (Adalimumab): The reporter's causality for the event of Scar and MAJOR PSORIASIS OUTBREAK was not provided. No treatment details were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Prostatomegaly, Sleep apnoea syndrome
Clinical narrative: Sleep apnea; Enlarged prostate; had COVID after taking 1st COVID vaccination shot; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (had COVID after taking 1st COVID vaccination shot), SLEEP APNOEA SYNDROME (Sleep apnea) and PROSTATOMEGALY (Enlarged prostate) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis.   In August 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced COVID-19 (had COVID after taking 1st COVID vaccination shot). On an unknown date, the patient experienced SLEEP APNOEA SYNDROME (Sleep apnea) and PROSTATOMEGALY (Enlarged prostate). In 2021, COVID-19 (had COVID after taking 1st COVID vaccination shot) had resolved. At the time of the report, SLEEP APNOEA SYNDROME (Sleep apnea) and PROSTATOMEGALY (Enlarged prostate) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product was reported. No treatment information was reported. It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the events with Humira was no reasonable possibility. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted
Clinical narrative: Missed 2nd Dose; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Missed 2nd Dose) and NO ADVERSE EVENT (No adverse event) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 13-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Missed 2nd Dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Missed 2nd Dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant and Treatment Drug was Provided by reporter.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 61.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Illness, Malaise
Clinical narrative: TOO SICK; NOT FEELING WELL; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (TOO SICK) and MALAISE (NOT FEELING WELL) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for an unknown indication.  No Medical History information was reported.   On 13-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 14-Apr-2022, the patient experienced MALAISE (NOT FEELING WELL). On an unknown date, the patient experienced ILLNESS (TOO SICK). At the time of the report, ILLNESS (TOO SICK) and MALAISE (NOT FEELING WELL) outcome was unknown.         This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  It was unknown patient enrolled in COVID-19 vaccine trial.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore upper left arm in the bicep; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (sore upper left arm in the bicep) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product VENETOCLAX (VENCLEXTA) for Acute myeloid leukemia.    Concurrent medical conditions included Acute myeloid leukemia.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started VENETOCLAX (VENCLEXTA) (Oral) at an unspecified dose. On 14-Apr-2022, the patient experienced PAIN IN EXTREMITY (sore upper left arm in the bicep). The patient was treated with PARACETAMOL (TYLENOL) for Pain in arm, at a dose of Extra-strength. At the time of the report, PAIN IN EXTREMITY (sore upper left arm in the bicep) had not resolved.            No concomitant medications were reported.  In August 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   Reported that extra-strength Tylenol was helpful.  It was unknown if he was enrolled in a Covid-19 Vaccine Trial. Reported that physician directed Venclexta seven days per month with infusion therapy and the 21 days off.   The reporter's causality for the event of let upper arm soreness with Venclexta(venetoclax) was a reasonable possibility.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Pain
Clinical narrative: Joints more achy hands/shoulders/knees and right wrist; Body aches; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Joints more achy hands/shoulders/knees and right wrist), PAIN (Body aches) and FATIGUE (Fatigue) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In January 2022, the patient experienced ARTHRALGIA (Joints more achy hands/shoulders/knees and right wrist), PAIN (Body aches) and FATIGUE (Fatigue). At the time of the report, ARTHRALGIA (Joints more achy hands/shoulders/knees and right wrist) had not resolved and PAIN (Body aches) and FATIGUE (Fatigue) was resolving.            It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Concomitant medications were not reported.  No treatment information was provided by the reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-631471 (Patient Link).   Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Hidradenitis suppurativa.    Concurrent medical conditions included Hidradenitis suppurativa.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous)  On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Concomitant medications were not reported.  No treatment information was provided by the reporter. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment: This is a spontaneous case concerning an adult male patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, after receiving a dose of mRNA-1273 vaccine. Exact date of vaccination, onset date of the event, clinical course, diagnostic tests and treatment details were not provided in the case. The event was resolving at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning an adult male patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, after receiving a dose of mRNA-1273 vaccine. Exact date of vaccination, onset date of the event, clinical course, diagnostic tests and treatment details were not provided in the case. The event was resolving at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Joint range of motion decreased, Neck pain, Pyrexia
Clinical narrative: Pain in neck, could not turn it all the way from side to side; Pain in neck, could not turn it all the way from side to side; Fatigue; Fever; This spontaneous case was reported by a consumer and describes the occurrence of JOINT RANGE OF MOTION DECREASED (Pain in neck, could not turn it all the way from side to side), NECK PAIN (Pain in neck, could not turn it all the way from side to side), FATIGUE (Fatigue) and PYREXIA (Fever) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 01-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Nov-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. On 21-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PYREXIA (Fever). On an unknown date, the patient experienced JOINT RANGE OF MOTION DECREASED (Pain in neck, could not turn it all the way from side to side), NECK PAIN (Pain in neck, could not turn it all the way from side to side) and FATIGUE (Fatigue). On 22-Feb-2021, PYREXIA (Fever) had resolved. At the time of the report, JOINT RANGE OF MOTION DECREASED (Pain in neck, could not turn it all the way from side to side) and NECK PAIN (Pain in neck, could not turn it all the way from side to side) had not resolved and FATIGUE (Fatigue) had resolved.            Concomitant product use was not provided by the reporter.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   The reporter's causality with Humira for the events of fatigue, pain in neck, could not turn it all the way from side to side and fever was not provided.  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Fatigue, Skin disorder
Clinical narrative: FATIGUE AFTER SECOND COVID DOSE; SPOT ON LEFT SHIN FLARE UP; FLARE UP ON HANDS/PALMS; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (FATIGUE AFTER SECOND COVID DOSE), SKIN DISORDER (SPOT ON LEFT SHIN FLARE UP) and CONDITION AGGRAVATED (FLARE UP ON HANDS/PALMS) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for an unknown indication.    No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Jul-2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 20-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FATIGUE (FATIGUE AFTER SECOND COVID DOSE), SKIN DISORDER (SPOT ON LEFT SHIN FLARE UP) and CONDITION AGGRAVATED (FLARE UP ON HANDS/PALMS). At the time of the report, FATIGUE (FATIGUE AFTER SECOND COVID DOSE) outcome was unknown and SKIN DISORDER (SPOT ON LEFT SHIN FLARE UP) and CONDITION AGGRAVATED (FLARE UP ON HANDS/PALMS) had not resolved.            No relevant concomitant medications were reported.   The reporter's causality for the events spot on left shin flare up and flare up on hands/palms with humira was reasonable possibility. The reporter's causality for the event fatigue after second covid dose was no reasonable possibility.  It was unknown if patient was enrolled in a COVID-19 vaccine trail  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Injection site burning/Pain during injection; Vaccination site pain, Injection site burning, Injection site pain; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Vaccination site pain, Injection site burning, Injection site pain) and VACCINATION SITE PAIN (Injection site burning/Pain during injection) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (MODERATE TO SEVERE RHEUMATOID ARTHRITIS).   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Apr-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous). On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. In 2021, the patient experienced VACCINATION SITE PAIN (Vaccination site pain, Injection site burning, Injection site pain). On an unknown date, the patient experienced VACCINATION SITE PAIN (Injection site burning/Pain during injection). At the time of the report, VACCINATION SITE PAIN (Vaccination site pain, Injection site burning, Injection site pain) and VACCINATION SITE PAIN (Injection site burning/Pain during injection) had resolved.            No concomitant medications were reported.   On unknown dates, the patient experienced burning on injection and hurting on injection. In 2021, the patient experienced sore arm from covid-19 vaccine. On unknown dates, sore arm from covid-19 vaccine, burning on injection and hurting on injection resolved. Moderna was also considered suspect.  It was unknown if patient was enrolled in covid-19 clinical trial  No treatment medication was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Acne, Nasopharyngitis, Pain in extremity, Pyrexia
Clinical narrative: blackhead; Cold; Hand pain; low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of ACNE (blackhead), NASOPHARYNGITIS (Cold), PAIN IN EXTREMITY (Hand pain) and PYREXIA (low grade fever) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    The patient's past medical history included Surgery (Rotator cuff) on 25-Oct-2021. Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe Rheumatoid arthritis ).   On 30-Oct-2020, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. In 2021, UPADACITINIB (RINVOQ) (Oral) dosage was changed to at an unspecified dose. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ACNE (blackhead), NASOPHARYNGITIS (Cold), PAIN IN EXTREMITY (Hand pain) and PYREXIA (low grade fever). At the time of the report, ACNE (blackhead) and PAIN IN EXTREMITY (Hand pain) had not resolved, NASOPHARYNGITIS (Cold) had resolved and PYREXIA (low grade fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  It was reported that, the patient had of rotator cuff surgery on left shoulder, pain in left hand, blackhead on back get infected and cold.  On 25-Oct-2021, the patient had a rotator cuff surgery on her left shoulder. The physician had instructed to hold Rinvoq before and after procedure. The patient would continue to follow physician orders and physical therapy. The patient also got a slight cold after low grade fever. She had pain especially in left hand. She had a blackhead on her back to get infected.  It was unknown if she was enrolled in a COVID-19 Vaccine Trial.   No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dehydration, Myalgia, Pain in extremity, Tension
Clinical narrative: This spontaneous case was reported by a patient and describes the occurrence of (Dehydrated), (Tense (Shoulder and arm pain), (Shoulder and arm pain) and (Felt achy) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for Prophylactic vaccination. Co-suspect product included non-company product DUPILUMAB solution for injection for Atopic dermatitis. The patient's past medical history included Injection site swelling from 27-Jul-2021 to 29-Jul-2021, Injection site burning from 27-Jul-2021 to 29-Jul-2021, Injection site tingling from 27-Jul-2021 to 29-Jul-2021 and Injection site warmth from 27-Jul-2021 to 29-Jul-2021. On 13-Jul-2021, the patient started (Subcutaneous) 600 milligrams. On 27-Jul-2021, (Subcutaneous) dosage was changed to 300 milligrams. On 01-Dec-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2021, the patient experienced (Dehydrated), (Dehydrated), (Tense (Shoulder and arm pain), (Shoulder and arm pain) and (Felt achy) had resolved.   Concomitant product use was not provided by the reporter. On 13-Jul-2021, the patient started taking Dupilumab injection initial loading dose with Dupixent single dose pre-filled pen. On 27-Jul-2021, the patient gave herself Dupilumab maintenance dose in the upper thigh. When the patient did the injection, the injection site felt swollen, there was like a burning and tingling sensation there, and it felt warm for about 2 days after the injection. There was no reported treatment and the event had been resolved. Dupixent was continued. On 30-Nov-2021, the patient had Dupixent injection. On 01-Dec-2021, the patient received Moderna booster dose and felt achy, dehydrated, tense, had shoulder and arm pain. They lasted for approximately 36 hours and resolved on 02-Dec-2021. On 28-Dec-2021, the patient took Dupixent, when heard the second click, counted to ten, the liquid came pouring out down her right leg and the site was swollen. The length of time that the product was allowed to come to room temperature was 45 minutes to an hour. The leaking was during administration with Dupixent. No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked in.
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination complication, Vaccination site haemorrhage
Clinical narrative: BAD SYMPTOMS AFTER MODERNA COVID VACCINE; BLEED MORE ON INJECTION; FELT NAUSEATED BUT NEVER THREW UP; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (BAD SYMPTOMS AFTER MODERNA COVID VACCINE), VACCINATION SITE HAEMORRHAGE (BLEED MORE ON INJECTION) and NAUSEA (FELT NAUSEATED BUT NEVER THREW UP) in an adult female patient who received mRNA-1273 for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Hidradenitis suppurativa.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced VACCINATION COMPLICATION (BAD SYMPTOMS AFTER MODERNA COVID VACCINE), VACCINATION SITE HAEMORRHAGE (BLEED MORE ON INJECTION) and NAUSEA (FELT NAUSEATED BUT NEVER THREW UP). At the time of the report, VACCINATION COMPLICATION (BAD SYMPTOMS AFTER MODERNA COVID VACCINE) and NAUSEA (FELT NAUSEATED BUT NEVER THREW UP) had not resolved and VACCINATION SITE HAEMORRHAGE (BLEED MORE ON INJECTION) outcome was unknown.        The action taken with mRNA-1273) (Intramuscular) was unknown.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant and treatment information was provided.  The reporter's causality for the events of felt nauseated but never threw up, bleed more on injection and  bad symptoms after moderna covid vaccine was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Diarrhoea, Feeling abnormal, Influenza like illness, Nasopharyngitis
Clinical narrative: FEELING LOUSY; LOSS OF APPETITE; Cold; Flu like symptoms; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (FEELING LOUSY), DECREASED APPETITE (LOSS OF APPETITE), INFLUENZA LIKE ILLNESS (Flu like symptoms), NASOPHARYNGITIS (Cold) and DIARRHOEA (Diarrhea) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In October 2021, the patient experienced DIARRHOEA (Diarrhea). On 19-Nov-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms). On an unknown date, the patient experienced FEELING ABNORMAL (FEELING LOUSY), DECREASED APPETITE (LOSS OF APPETITE) and NASOPHARYNGITIS (Cold). At the time of the report, FEELING ABNORMAL (FEELING LOUSY) outcome was unknown and DECREASED APPETITE (LOSS OF APPETITE), INFLUENZA LIKE ILLNESS (Flu like symptoms), NASOPHARYNGITIS (Cold) and DIARRHOEA (Diarrhea) had not resolved.            Concomitant product use was not provided by the reporter. The patient received booster dose of Moderna vaccine. On unknown dates, the patient experienced feeling lousy, loss of appetite and cold. In October-2021, the patient experienced diarrhea. On 19-Nov-2021, the patient experienced flu like symptoms.  No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.      Reporter did not allow further contact
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Joint noise, Malaise, Suspected COVID-19, Vaccination site pain
Clinical narrative: COVID VACCINES CAUSED TO NOT FEEL SO WELL; CAUSED TO HAVE COVID SYMPTOMS; COVID BOOSTER VACCINE MADE ARM REALLY HURT; FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS; FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS AND WAS IN EXTREME PAIN; This spontaneous case was reported by a consumer and describes the occurrence of JOINT NOISE (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS), MALAISE (COVID VACCINES CAUSED TO NOT FEEL SO WELL), SUSPECTED COVID-19 (CAUSED TO HAVE COVID SYMPTOMS), ARTHRALGIA (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS AND WAS IN EXTREME PAIN) and VACCINATION SITE PAIN (COVID BOOSTER VACCINE MADE ARM REALLY HURT) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Posterior uveitis.    Concurrent medical conditions included Posterior uveitis.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) CF Pen. In December 2021, the patient experienced JOINT NOISE (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS) and ARTHRALGIA (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS AND WAS IN EXTREME PAIN). On an unknown date, the patient experienced MALAISE (COVID VACCINES CAUSED TO NOT FEEL SO WELL), SUSPECTED COVID-19 (CAUSED TO HAVE COVID SYMPTOMS) and VACCINATION SITE PAIN (COVID BOOSTER VACCINE MADE ARM REALLY HURT). At the time of the report, JOINT NOISE (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS) and ARTHRALGIA (FELT A POP IN HIP WHEN WAS GOING UP THE STAIRS AND WAS IN EXTREME PAIN) had not resolved and MALAISE (COVID VACCINES CAUSED TO NOT FEEL SO WELL), SUSPECTED COVID-19 (CAUSED TO HAVE COVID SYMPTOMS) and VACCINATION SITE PAIN (COVID BOOSTER VACCINE MADE ARM REALLY HURT) had resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   There was no reported medical history.  Concomitant medication was not provided.  No information regarding treatment medication was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, COVID-19, Hypertension, Viral test
Clinical narrative: Hypertension; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) and HYPERTENSION (Hypertension) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.  Concurrent medical conditions included Non-smoker and Abstains from alcohol. Concomitant products included ESOMEPRAZOLE MAGNESIUM TRIHYDRATE (NEXIUM [ESOMEPRAZOLE MAGNESIUM TRIHYDRATE]) for Gastroesophageal reflux disease, LEFLUNOMIDE and PREDNISONE for Rheumatoid arthritis.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In September 2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) (40 mg,1 in 2 wk). On 06-Jan-2022, the patient experienced COVID-19 (COVID-19). On 28-Jan-2022, the patient experienced HYPERTENSION (Hypertension). The patient was treated with LOSARTAN at an unspecified dose and frequency; GUAIFENESIN (MUCINEX) at an unspecified dose and frequency; DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN (TUSSIN DM) at an unspecified dose and frequency and HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE & HCTZ) at an unspecified dose and frequency. In January 2022, COVID-19 (COVID-19) had resolved. At the time of the report, HYPERTENSION (Hypertension) had not resolved.   DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jan-2022, Viral test: Positive. On 26-Jan-2022, Viral test: Negative. On an unknown date, Blood pressure measurement: Blood pressure raised to 173/72.         This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in   It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Primary reporter did not have the lot number information, because the packaging was discarded  No known allergies  The reporter's causality for the event(s) of COVID-19 and HYPERTENSION with HUMIRA 40MG/0.4ML(ADALIMUMAB) was no reasonable possibility.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Inflammatory marker increased, Inflammatory marker test, Rash, Rash papular
Clinical narrative: FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL; FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL; SPIKES IN INFLAMMATORY MARKERS SHORTLY; This spontaneous case was reported by a consumer and describes the occurrence of RASH PAPULAR (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL), RASH (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL) and INFLAMMATORY MARKER INCREASED (SPIKES IN INFLAMMATORY MARKERS SHORTLY) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    No Medical History information was reported.   In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In October 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced RASH PAPULAR (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL), RASH (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL) and INFLAMMATORY MARKER INCREASED (SPIKES IN INFLAMMATORY MARKERS SHORTLY). At the time of the report, RASH PAPULAR (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL) had not resolved and RASH (FACE WAS BREAKING OUT WITH LITTLE BUMPS UNDER THE SKIN THAT WERE PAINFUL) and INFLAMMATORY MARKER INCREASED (SPIKES IN INFLAMMATORY MARKERS SHORTLY) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Inflammatory marker test: Spike in Inflammatory Markers.         This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in   It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter's causality for the event(s) of face was breaking out with little bumps under the skin that were painful and spikes in inflammatory markers shortly after the first and second covid vaccines with rinvoq (upadacitinib) was no reasonable possibility.   No concomitant medication was provided by reporter. No treatment medication was provided by reporter.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Hidradenitis, White blood cell count, White blood cell count increased
Clinical narrative: WHITE BLOOD CELLS WERE ELEVATED; HIDRADENITIS SUPPURATIVA FLARE UP; This spontaneous case was reported by a consumer and describes the occurrence of WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED) and HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In January 2021, the patient experienced HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP). On an unknown date, the patient experienced WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED). In January 2021, HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP) had resolved. At the time of the report, WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, White blood cell count: Elevated.         It was unknown if the patient was enrolled in covid-19 vaccine trials.  No concomitant product reported by reporter.  Patient experienced hidradenitis suppurativa flare up after first covid vaccine.  No treatment medication reported by reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Eczema, Vaccination site pain
Clinical narrative: Eczema; Vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (Eczema) and VACCINATION SITE PAIN (Vaccination site pain) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Solution for injection in pre-filled pen, Citrate Free. On an unknown date, the patient experienced ECZEMA (Eczema) and VACCINATION SITE PAIN (Vaccination site pain). At the time of the report, ECZEMA (Eczema) and VACCINATION SITE PAIN (Vaccination site pain) outcome was unknown.            On an unknown date, the patient had eczema on legs and sore arm after Covid vaccination.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.